Proportion of patients with patent parasitaemia | Parasite positivity rate | ||||
---|---|---|---|---|---|
Number of study arms | Median % | [Range,IQR] | |||
Africa | |||||
Day 1 | 53.2% | (6,694/12,576) | 76 | 48.9% | [Range: 2.6-94.4 IQR: 26.6-66.4] |
Day 2 | 8.3% | (1,575/19,044) | 111 | 6.1% | [Range: 0–65.9, IQR: 1.6-11.2 ] |
7.9% | (1,456/18,466) | 107 | 6.0% | [Range: 0–65.9, IQR: 1.6-11.0 ] | |
Day 3 | 1.0% | (238/18,593) | 115 | 0% | [Range: 0–36.5, IQR: 0–1.2 ] |
1.0% | (176/17,223) | 107 | 0% | [Range: 0–10.0, IQR: 0–1.2 ] | |
Asia | |||||
Day 1 | 59.0% | (2,794/4,733) | 30 | 59.9% | [Range: 0—84.3, IQR: 37.7-74.0] |
59.5% | (2,793/4,691) | 28 | 61.6% | [Range: 16.4—84.3, IQR: 41.1-74.0] | |
Day 2 | 12.2% | (808/6,608) | 45 | 8.9% | [Range: 0–72.5, IQR: 3.3-20.8] |
Day 3 | 3.8% | (247/6,651) | 45 | 1.1% | [Range: 0–55.0, IQR: 0–5.3] |
3.8% | (243/6,399) | 41 | 1.7% | [Range: 0–55.0, IQR: 0–5.6] | |
South America | |||||
Day 1 | 39.6% | (237/598) | 5 | 48.0% | [Range: 32.3-75.0, IQR=41.5-48.0] |
Day 2 | 6.0% | (43/719) | 7 | 4.0% | [Range: 0–21.4, IQR=1.1-17.9] |
Day 3 | 1.0% | (10/1044) | 11 | 0% | [Range: 0–8.6, IQR=0-2.1] |